NEW YORK (GenomeWeb News) – CombiMatrix today priced its public offering of 12,000 units of preferred of Series D convertible preferred stock and warrants at a price of $1,000 per unit.

Gross proceeds from the offering are $12 million, with net proceeds anticipated to be $10.8 million. The array-based molecular diagnostics developer said that it expects to close the offering on or around Dec. 20.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.